SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 14th, 2022 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
Contract Type FiledApril 14th, 2022 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of April 13, 2022, between NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD.Common Share Purchase Warrant • April 14th, 2022 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations
Contract Type FiledApril 14th, 2022 Company IndustryTHIS COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. (New York City time) on October [__], 20271 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), up to [____] Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD.Pre-Funded Common Share Purchase Warrant • April 14th, 2022 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations
Contract Type FiledApril 14th, 2022 Company IndustryTHIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), up to [____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Shares. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Private Placement of Common Share Purchase WarrantsPlacement Agent Agreement • April 14th, 2022 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
Contract Type FiledApril 14th, 2022 Company Industry JurisdictionThis letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and NLS Pharmaceutics Ltd., a company organized under the laws of Switzerland (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of common shares of the Company, par CHF 0.02 per share (the “Common Shares”), any pre-funded warrants to purchase common shares (“Pre-Funded Warrants”), and the common share purchase warrants to purchase Common Shares (the “Investor Warrants”, and together with the Common Shares and Pre-Funded Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein con